Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder—A preliminary report

Dávila, Ricardo; Zumárraga, Mercedes; Basterreche, Nieves; Arrúe, Aurora; Zamalloa, María Isabel; Anguiano, Juan B.

doi:10.1016/j.jad.2006.02.009

Cited by 21 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same study also found a positive association between the glutamate receptor metabotropic 3 (GRM3) gene (polymorphism rs6465084) and an increased risk of lifetime history of psychosis in BPAD patients in the case‐only analysis, without reaching statistically significant results when comparing BD‐P with BD‐NP . Furthermore, neither the FK506 binding protein 5 (FKBP5) gene (FKBP5 regulates the activity of the glucocorticoid receptor) nor the catechol‐O‐methyl transferase (COMT) Val108/158Met genotype were associated with congruent/incongruent BD‐P …”

Section: Resultsmentioning

confidence: 99%

Biological aspects and candidate biomarkers for psychotic bipolar disorder: A systematic review

Buoli

Caldiroli

Melter

et al. 2016

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Aim:We carried out a systematic review of the available literature about potential biomarkers of psychotic bipolar disorder (BD-P), a specific subset presenting worse outcome and greater risk of relapse than non-psychotic bipolar disorder (BD-NP). Methods:We searched the main psychiatric databases (PubMed, ISI Web of Knowledge, PsychInfo). Only original articles with the main topic of BD-P compared to schizophrenia/BD-NP/healthy controls (HC) written in English from 1994 to 2015 were included.Results: BD-P patients presented higher kynurenic acid levels in the cerebrospinal fluid, elevated antiSaccharomyces cerevisiae antibodies levels, and lower serum levels of dehydroepiandrosterone sulfate and progesterone than BD-NP/HC. Event-related potentials abnormalities have been identified in BD-P with respect to BD-NP. BD-P patients also presented bigger ventricles but similar hippocampal volumes compared to BD-NP/HC. Although the results are contrasting, some cognitive deficits seemed to be related to the psychotic dimension of bipolar affective disorder, such as impairment in verbal/logical memory, working memory, verbal and semantic fluency and executive functioning. Finally, polymorphisms of genes, such as NRG1, 5HTTLPR (s), COMT, DAOA and some chromosome regions (16p12 and 13q), were positively associated with BD-P. Conclusion:Data about the identification of specific biomarkers for BD-P are promising, but most of them have not yet been replicated. They could lead the clinicians to an early diagnosis and proper treatment, thus ameliorating outcome of BD-P and reducing the biological changes associated with a long duration of illness. Further studies with bigger samples are needed to detect more specific biological markers of the psychotic dimension of bipolar affective disorder.Key words: biomarkers, bipolar disorder, psychoneurobiology, psychopathology, psychotic symptoms. B IOLOGICAL MARKERS, AS indicators of a biological or a pathological state and as parameters that can be measured objectively, could provide a valuable support to the clinical decision-making process in many branches of medicine, including psychiatry. Several findings in the field of mood disorders could provide the background for the identification of potential specific and objective biomarkers, which could be an important aid to better understand the course of illness, the mechanisms of vulnerability and of disease expression.A recent paper describing the work of the Biomarkers Network from the International Society for Bipolar Disorders (ISBD-BIONET) cited neuroimaging and genetic findings in bipolar affective disorder (BPAD) (e.g. the loss of gray matter, the altered activation of anterior temporal, ventral prefrontal and subcortical regions in response to emotional stimuli, the identification of several potential candidate genes associated with increased risk for developing *Correspondence: Alice Caldiroli, MD, Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, via Francesco Sforza ...

show abstract

Section: Resultsmentioning

confidence: 99%

Biological aspects and candidate biomarkers for psychotic bipolar disorder: A systematic review

Buoli

Caldiroli

Melter

et al. 2016

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

“…The low‐activity allele may be linked to a susceptibility to BD, although meta‐analysis would suggest that the effect size is very modest (247). The presence of the low‐activity allele has been associated with the occurrence of rapid cycling (248, 249) and ultra‐rapid cycling (220) in patients with BD, suggesting that it may be a course modifier (247), but negative findings have been reported (250). There have recently been negative reports on the contribution of genotype to executive function in BD (251).…”

Section: Genes Dopamine and Bipolar Disordermentioning

confidence: 99%

The role of dopamine in bipolar disorder

2009

View full text Add to dashboard Cite

show abstract

“…136 Lack of association was reported for patients with bipolar 1 disorder. 137 Table 4 reports the main association studies that dealt with the effect of COMT variations on antidepressant response.…”

Section: Catechol-o-methyl Transferasementioning

confidence: 99%

Pharmacogenetics of Antidepressant Response

Serretti

Drago

Liebman

2008

Biomarkers for Psychiatric Disorders

View full text Add to dashboard Cite

Personalized medicine-the adaptation of therapies based on an individual's genetic and molecular profile-is one of the most promising aspects of modern medicine. The identification of the relation between genotype and drug response, including both the therapeutic effect and side effect profile, is expected to deeply affect medical practice. In this paper, we review the current knowledge about the genes related to antidepressant treatment response and provide methodologic proposals for future studies. We have mainly focused on genes associated with pharmacodynamics, for which a list of promising genes has been identified despite some inconsistency across studies. We have also synthesized the main results for pharmacokinetic genes, although so far they seem less relevant than those for pharmaco dynamic genes. We discuss possible reasons for these inconsistent findings and propose new study designs.

show abstract

Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder—A preliminary report

Cited by 21 publications

References 25 publications

Biological aspects and candidate biomarkers for psychotic bipolar disorder: A systematic review

Biological aspects and candidate biomarkers for psychotic bipolar disorder: A systematic review

The role of dopamine in bipolar disorder

Pharmacogenetics of Antidepressant Response

Contact Info

Product

Resources

About